{
  "success": true,
  "pagesUsed": [
    9,
    10,
    11,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "claude-opus-4-5",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Pharmacokinetic Objective",
        "text": "To evaluate the pharmacokinetics (PK) of subcutaneous (SC) ramucirumab in participants with cancer",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2",
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Safety Objective",
        "text": "To evaluate the safety of SC ramucirumab in participants with cancer, alone or in combination with additional anti-cancer therapy",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4",
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective",
        "text": "To evaluate the efficacy of SC ramucirumab in participants with cancer",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_6",
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Exploratory Immunogenicity Objective",
        "text": "To evaluate the immunogenicity of SC ramucirumab",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Ramucirumab Ctrough",
        "text": "Ramucirumab trough concentration (Ctrough) following SC administration",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_2",
        "name": "Ramucirumab AUC",
        "text": "Ramucirumab area under the plasma concentration versus time curve (AUC) following SC administration",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_3",
        "name": "Ramucirumab Cmax",
        "text": "Ramucirumab maximum concentration (Cmax) following SC administration",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_4",
        "name": "Treatment-Emergent Adverse Events",
        "text": "Incidence and severity of treatment-emergent adverse events (TEAEs)",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Injection Site Reactions",
        "text": "Incidence and severity of injection site reactions following SC ramucirumab administration",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_6",
        "name": "Progression-Free Survival",
        "text": "Progression-free survival (PFS)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "Overall Survival",
        "text": "Overall survival (OS)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Immunogenicity Assessment",
        "text": "Immunogenicity assessments including anti-drug antibody formation",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 2,
      "secondaryObjectives": 1,
      "exploratoryObjectives": 1,
      "totalEndpoints": 8,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Pharmacokinetic Objective",
        "text": "To evaluate the pharmacokinetics (PK) of subcutaneous (SC) ramucirumab in participants with cancer",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_1",
          "ep_2",
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Primary Safety Objective",
        "text": "To evaluate the safety of SC ramucirumab in participants with cancer, alone or in combination with additional anti-cancer therapy",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_4",
          "ep_5"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Efficacy Objective",
        "text": "To evaluate the efficacy of SC ramucirumab in participants with cancer",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_6",
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Exploratory Immunogenicity Objective",
        "text": "To evaluate the immunogenicity of SC ramucirumab",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Exploratory Objective"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Ramucirumab Ctrough",
        "text": "Ramucirumab trough concentration (Ctrough) following SC administration",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_2",
        "name": "Ramucirumab AUC",
        "text": "Ramucirumab area under the plasma concentration versus time curve (AUC) following SC administration",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_3",
        "name": "Ramucirumab Cmax",
        "text": "Ramucirumab maximum concentration (Cmax) following SC administration",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_4",
        "name": "Treatment-Emergent Adverse Events",
        "text": "Incidence and severity of treatment-emergent adverse events (TEAEs)",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_5",
        "name": "Injection Site Reactions",
        "text": "Incidence and severity of injection site reactions following SC ramucirumab administration",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_6",
        "name": "Progression-Free Survival",
        "text": "Progression-free survival (PFS)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_7",
        "name": "Overall Survival",
        "text": "Overall survival (OS)",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_8",
        "name": "Immunogenicity Assessment",
        "text": "Immunogenicity assessments including anti-drug antibody formation",
        "level": {
          "code": "Exploratory",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Exploratory Endpoint"
        },
        "purpose": "Biomarker",
        "instanceType": "Endpoint"
      }
    ],
    "estimands": []
  }
}